Literature DB >> 18462259

Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas.

Young Suk Jo1, Songmei Huang, Yun-Jeung Kim, Ihn-Suk Lee, Song-Soo Kim, Je-Ryong Kim, Taejeong Oh, Youngho Moon, Sungwhan An, Heung-kyu Ro, Jin-Man Kim, Minho Shong.   

Abstract

CONTEXT: Dideoxy sequencing is the most commonly used method for detecting the BRAF(V600E) mutation in thyroid cancer and melanoma. However, this gold standard method often makes less definite results in detecting the BRAF(V600E) mutation when there are relatively low amounts of the mutant template in biopsy specimens, which are invariably contaminated with normal tissues. Pyrosequencing, which measures the incorporation of each of the four nucleotides at each template position and indicates the amounts of mutant template present, may be more useful in such situations.
OBJECTIVE: To investigate the diagnostic efficiency of pyrosequencing for the mutant BRAF allele in ultrasound (US)-guided fine needle aspiration biopsies (FNABs) of thyroid incidentalomas. DESIGN, SETTING AND
SUBJECTS: A total of 101 thyroid incidentaloma cases were included prospectively. Cytological diagnoses of the FNAB samples were made according to the American Thyroid Association (ATA) guidelines, 2006. The presence of the BRAF(V600E) mutation was investigated by pyrosequencing and dideoxy sequencing.
RESULTS: On the basis of cytological analysis, the thyroid incidentalomas were classified into benign (n = 43), malignant (n = 30), indeterminate or suspicious neoplasm (n = 24), and nondiagnostic (n = 4) categories. Pyrosequencing detected the BRAF(V600E) mutation in 30 cases: 22 malignant cases, 7 indeterminate cases, and 1 nondiagnostic case. Dideoxy sequencing also detected the BRAF(V600E) mutation in 28 of the same cases but failed to clearly distinguish the mutant allele from the wild-type allele in one indeterminate case and one nondiagnostic case. Histopathological analysis ascertained that all BRAF(V600E)-positive cases were papillary thyroid carcinomas.
CONCLUSIONS: Pyrosequencing may be suitable for detecting the BRAF(V600E) mutation in thyroid incidentaloma and may be superior to dideoxy sequencing when low amounts of the mutant template are present in the biopsy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18462259     DOI: 10.1111/j.1365-2265.2008.03293.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  20 in total

Review 1.  Molecular analysis of thyroid tumors.

Authors:  Feriyl Bhaijee; Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2011-09       Impact factor: 3.943

Review 2.  Molecular testing in the diagnosis of differentiated thyroid carcinomas.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Ilaria Ruffilli; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Salvatore Ulisse; Enke Baldini; Riccardo Giannini; Paolo Miccoli; Alessandro Antonelli; Fulvio Basolo
Journal:  Gland Surg       Date:  2018-08

Review 3.  Molecular genetics and diagnosis of thyroid cancer.

Authors:  Yuri E Nikiforov; Marina N Nikiforova
Journal:  Nat Rev Endocrinol       Date:  2011-08-30       Impact factor: 43.330

4.  A more sensitive platform for the detection of low-abundance BRAF(V⁶⁰⁰E) mutations.

Authors:  Weiqin Jiang; Weibin Wang; Fangfang Fu; Xiaodong Teng; Haohao Wang; Haiyong Wang; Lisong Teng
Journal:  Mol Cell Biochem       Date:  2012-03-15       Impact factor: 3.396

5.  The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas.

Authors:  Bülent Kurt; Serap Yalçın; Engin Alagöz; Yıldırım Karslıoğlu; Nuri Yigit; Armağan Günal; M Salih Deveci
Journal:  Endocr Pathol       Date:  2012-09       Impact factor: 3.943

6.  Incidental finding of papillary thyroid carcinoma with BRAFV600E mutation in a patient with coexistent primary hyperparathyroidism and Graves' hyperthyroidism.

Authors:  Yayi He; Shu Liu; Hui Guo; Bingyin Shi
Journal:  BMJ Case Rep       Date:  2014-05-30

7.  BRAF V600E mutation correlates with aggressive clinico-pathological features but does not influence tumor recurrence in papillary thyroid carcinoma-10-year single-center results.

Authors:  Navid Tabriz; Johannes Grone; Verena Uslar; Andrea Tannapfel; Dirk Weyhe
Journal:  Gland Surg       Date:  2020-12

Review 8.  The utility of BRAF testing in the management of papillary thyroid cancer.

Authors:  Adrienne L Melck; Linwah Yip; Sally E Carty
Journal:  Oncologist       Date:  2010-12-08

9.  Prediction Table and Nomogram as Tools for Diagnosis of Papillary Thyroid Carcinoma: Combined Analysis of Ultrasonography, Fine-Needle Aspiration Biopsy, and BRAF V600E Mutation.

Authors:  Seo Ki Kim; Jun Ho Lee; Jung-Woo Woo; Inhye Park; Jun-Ho Choe; Jung-Han Kim; Jee Soo Kim
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

Review 10.  B-Raf and the inhibitors: from bench to bedside.

Authors:  Tiangui Huang; Michael Karsy; Jian Zhuge; Minghao Zhong; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-04-25       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.